Med Ed Report

Why no Bad-Ad Program letters?

By

While two dozen enforcement letters were sent by FDA's Office of Prescription Drug Promotion to pharma companies last year, up from 21 in 2012, none of the letters were prompted by the Bad Ad Program.

Med Ed Report briefs: June 2014

Med Ed Report briefs: June 2014

News on the University of Louisville CME program, Merck, GlobalData and BroadcastMed

Teachable moment for new allergy tabs

Teachable moment for new allergy tabs

By

With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.

Pharma preps for Sunshine inquiries

Pharma preps for Sunshine inquiries

By

Firms are gearing up for the detailed filing of Sunshine data later this year, after which the inquiries and disputes window will begin.

Cardio educational website from Bayer makes its debut

Cardio educational website from Bayer makes its debut

By

Bayer HealthCare launched an educational website for US physicians about the rare, life-threatening condition chronic thromboembolic pulmonary hypertension (CTEPH).

Med Ed Report briefs: May 2014

Med Ed Report briefs: May 2014

By

News on HHS, ACCME, Haymarket Medical Education and Smith & Nephew

Speaker pay sharply cut: ProPublica

By

The approach of new transparency rules, coupled with patent losses and industry's shift to specialty meds, has contributed to a big drop in the amount drugmakers are spending on promotional speaking, says ProPublica.

A research gap for rare diseases

By

There is an "overwhelming need" among HCPs for greater awareness, training and education on the diagnosis and available treatment options for rare diseases, researchers suggest.

Alexion ramps up med-ed for HPP drug

Alexion ramps up med-ed for HPP drug

By

Alexion is focusing on medical education ahead of an anticipated approval of asfotase alfa for patients with hypophosphatasia, or HPP

Med Ed Report briefs: March 2014

Med Ed Report briefs: March 2014

By

News on the CBI Pharmaceutical Compliance Congress, Eli Lilly and New York TImes

ACCME revisits commercial logo ban

ACCME revisits commercial logo ban

By

The ACCME announced a public call for comment about its proposal to simplify the accreditation requirements and process, including revisiting a ban on commercial support logos.

CMS: journal reprints fall outside of Sunshine exclusion

CMS: journal reprints fall outside of Sunshine exclusion

By

It looks like, for now, journal reprints and medical textbooks are reportable items under the Sunshine Act.

Med Ed Report briefs: February 2014

Med Ed Report briefs: February 2014

By

News on the Federation of State Medical Boards, Haymarket Medical Education, ACCME and the Audio-Digest Foundation

Companies view Sunshine differently

Companies view Sunshine differently

By

A report indicates pharma companies do not agree on what research needs to be reported.

House members voice opposition to CMS reprints stance

House members voice opposition to CMS reprints stance

By

Nearly two dozen members of Congress signaled solidarity with 41 medical boards and 33 physician associations in opposing the inclusion of textbooks and reprints in Sunshine Act reporting.

Med Ed Report briefs: January 2014

Med Ed Report briefs: January 2014

By

News on CME Coalition, Haymarket Medical Education, American Academy of Physician Assistants and Physicians Interactive

Conflicts seen on guidelines panel

By

The AHA/ACC panel that wrote the potentially practice-changing cholesterol guidelines issued last month included six members with ties to drugmakers that sell or are developing lipid medications, Pharmalot reported.

Med Ed Report briefs: December 2013

Med Ed Report briefs: December 2013

By

News on Bayer Healthcare, Onyx Pharmaceuticals, Lilly, J&J, CMS and Community Care Behavioral Health Organization

J&J HCV drug OK'd; educational push planned

J&J HCV drug OK'd; educational push planned

By

Janssen's hepatitis C drug Olysio (simeprevir) offers modest benefit over standard of care, but resistance in a subgroup of patients could hinder broader uptake.

Many unclear on 2013 Sunshine data

Many unclear on 2013 Sunshine data

By

A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.

Janssen, BI fund AFib ed. initiative

By

The North American Thrombosis Forum (NATF) launched an educational initiative on risk assessment and anticoagulation for stroke prevention in atrial fibrillation (AF).

Bonuses might boost MD quality

By

Executives from the Massachusetts General Physicians Organization said their incentive program for salaried physicians boosted clinical quality.

Med Ed Report briefs: November 2013

Med Ed Report briefs: November 2013

By

News on Oakstone Publishing, ArcheMedx, Conventus, CircleScience and AxoGen

OPDP expands "Bad Ad" with CME

OPDP expands "Bad Ad" with CME

By

The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.

Rebound seen in HCP meeting turnout: report

Rebound seen in HCP meeting turnout: report

By

Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.

Compliance up, tougher rules loom

Compliance up, tougher rules loom

By

Providers of CME are getting better at complying with accreditation criteria, several years' worth of data show, yet tougher criteria may be in store.

Now appearing in operating theaters: Google Glass

Now appearing in operating theaters: Google Glass

By

In addition to donning scrubs before entering the OR, several surgeons have slipped on Google Glass, the augmented-reality enabling goggles.

Med Ed Report briefs: October 2013

Med Ed Report briefs: October 2013

By

News on Elsevier, CDC, Southern Medical Association and Astellas

CME income up, despite pharma cuts

CME income up, despite pharma cuts

By

Though CME grant-giving dropped by about 10% in 2012, revenues from regsitration fees and the like surged nearly 15%

MyCME brings secondary topics up

By

Haymarket Medical Education is taking the wraps off a totally redesigned MyCME.com portal this month

Keep REMS ed optional: AAFP

By

The AAFP has urged FDA to keep REMS-specific CME for extended-release and long-acting opioids voluntary

Med Ed Report briefs: September 2013

Med Ed Report briefs: September 2013

By

News about Pri-Med, Astellas Scientic, Medical Affairs, UCSD and CircleScience

CME may save money, study says

CME may save money, study says

By

A study by CMEology shows that CME can trim substantial costs from the healthcare system

CMS clarifies Sunshine excludability

By

CMS has clarified how meals and expenses are to be treated under the so-called CME exemption

ProPublica looks at the Rx-$ nexus

By

ProPublica data show that a number of drug prescribers receive money from drug companies for promotional talks

Med Ed Report briefs: August 2013

Med Ed Report briefs: August 2013

By

News on Clinical Care Options, Global Academy for Medical Education, Association of American Medical Colleges, American Psychological Association and KnowledgePoint360

BI, Lilly diabetes push keeps it simple

BI, Lilly diabetes push keeps it simple

By

Boehringer Ingelheim and Eli Lilly rolled out a pre-launch med-ed campaign to differentiate their positioning in the SGLT2 diabetes drug class.

MSLs deployed in launch of Navidea diagnostic agent

MSLs deployed in launch of Navidea diagnostic agent

By

Navidea Biopharmaceuticals is launching Lymphoseek, its diagnostic agent used to check for cancer spread, with medical affairs, promotional education and CME aimed at the nuclear medicine community.

Med Ed Report briefs: June 2013

Med Ed Report briefs: June 2013

By

News on the Australian Medical Association, Sanofi, GAME, Novartis and KnowledgePoint 360

Patent woes take a toll on speaking

Patent woes take a toll on speaking

By

For Pfizer and GlaxoSmithKline, the effects of expiring patents on blockbuster drugs took their toll on payments to US doctors last year.

Median time to publication: 21 mos.

By

It takes nearly two years for results from the average clinical trial to be published, across all funders, according to a new study.

Did Cephalon use fake ad-boards?

By

A whistleblower says Cephalon used CME, "bogus 'market research surveys' and Advisory Board meetings" to disseminate an off-label message about Treanda to prescribers.

Med Ed Report briefs: May 2013

Med Ed Report briefs: May 2013

By

News on Pfizer, Novartis, Teva, SternScientific, Roche and the PharmedOut Conference

ProPublica: firms paid $2B+ to docs

ProPublica: firms paid $2B+ to docs

By

ProPublica's Dollars for Docs database shows many firms continue to utilize physician speakers for non-CME product-related talks and consulting.

CV, asthma brands take meeting lead

By

Although a popular part of the mix for some brands, meetings drew fewer dollars from pharma's coffers last year, according to research.

UK panel acquits Roche staffers

By

A panel following up on an anonymous complaint to UK industry self-policing arm PCMPA ruled for Roche in a case alleging inappropriate behavior at an overseas medical conference.

Med Ed Report briefs: April 2013

Med Ed Report briefs: April 2013

By

News on Pri-Med, Exhibitor magazine, Boehringer Ingelheim, QPharma and Elsevier

Peer education in Sunshine's glare

Peer education in Sunshine's glare

By

The final ruling regarding collecting data on industry payments to physicians from HHS's Centers for Medicare & Medicaid Services has several elements that are significant for medical education.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters